Sentencing Delayed for Florida Retina Specialist Melgen

August 11, 2017: By Joan McKenna
Salomon Melgen

Salomon Melgen

A sentencing hearing for Florida retina specialist Salomon Melgen was postponed Aug. 10, a day before it was to set to start.

Melgen’s lawyers said in court documents filed Aug. 10 that all parties agreed to move the hearing to Dec. 4-6 due Melgen’s upcoming trial in New Jersey and the schedules of counsel.

Melgen’s joint trial on bribery charges with US Sen. Robert Menendez, D-NJ, is slated to begin Sept. 6.

In Florida, Melgen, 62, was convicted in April by a federal jury of 67 counts of Medicare fraud.

Melgen was accused of falsely diagnosing patients with macular degeneration and other retinal disorders, performing unnecessary procedures, and overcharging for Lucentis vials.

US prosecutors alleged that, between January 2008 and December 2013, Melgen billed Medicare for more than $190 million, for which he was reimbursed more than $105 million. The government said a substantial portion of these payments were obtained through fraudulent billing.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022